Evidence map›Paper›PMID 32277442›Full record

ArticleMolecular biology reports2020

A comparative molecular analysis of DNA damage response, cell cycle progression, viability and apoptosis of malignant granulosa cells exposed to gemcitabine and cisplatin.

Gamze Bildik, Yashar Esmaeilian, Dogan Vatansever, Esra Bilir, Cagatay Taskiran, Ozgur Oktem

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. FTO protects human granulosa cells from chemotherapy-induced cytotoxicity.Reproductive biology and endocrinology : RB&E · 2022
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Gamze BildikGraduate School of Health Sciences, Koc University, Istanbul, 34450, Turkey.
Yashar EsmaeilianResearch Center for Translational Medicine, Koc University, Istanbul, 34450, Turkey.
Dogan VatanseverDepartment of Obstetrics and Gynecology, Koc University School of Medicine, Istanbul, 34450, Turkey.
Esra BilirGraduate School of Health Sciences, Koc University, Istanbul, 34450, Turkey.
Cagatay TaskiranDepartment of Obstetrics and Gynecology, Koc University School of Medicine, Istanbul, 34450, Turkey.
Ozgur OktemGraduate School of Health Sciences, Koc University, Istanbul, 34450, Turkey. ooktem@ku.edu.tr.
Koç University · TRThe University of Texas MD Anderson Cancer Center · US

Funding

Koc University Research Center for Translational Medicine -
6 · The paper itself

Abstract

We aimed to provide a comparative characterization of DNA damage response elements, survival/apoptosis and cell cycle progression of the malignant granulosa cells exposed to gemcitabine and cisplatin. Malignant granulosa tumor cell lines COV434 and KGN were used for the experiments. Cell viability, proliferation, DNA damage response and apoptosis were investigated. Cell cycle progression was assessed. In vitro estradiol (E

Indexed as

Antineoplastic AgentsApoptosisCell CycleCell Line, TumorCell ProliferationCell SurvivalCisplatinDeoxycytidineDNA DamageDNA RepairFemaleG2 Phase Cell Cycle CheckpointsGemcitabineGranulosa CellsGranulosa Cell TumorHumansAntineoplastic AgentsCisplatinDeoxycytidineGemcitabineAnti-mullerian hormoneApoptosisCisplatinCOV434EstradiolGemcitabineGranulosa cell tumorKGN

Identifiers

PMID32277442
OpenAlexW3016214554

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.